Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934008 | 0.90 | NR1H2 (0.50) | HPGDRECQLEPHX1CHRM2CHRM1 | |
| SCHEMBL27456630 | 0.90 | NR1H2 (0.50) | HPGDRECQLEPHX1CHRM2CHRM1 | |
| SCHEMBL31208756 | 0.84 | HPGD (0.46) | HPGDRECQLEPHX1CHRM2CHRM1 | |
| SCHEMBL31209483 | 0.84 | HPGD (0.48) | HPGDRECQLEPHX1CHRM2CHRM1 | |
| SCHEMBL27031139 | 0.84 | NR1H2 (0.45) | HPGDRECQLEPHX1CHRM2CHRM1 | |
| SCHEMBL31208998 | 0.82 | HPGD (0.43) | HPGDRECQLEPHX1MAPTALDH1A1 | |
| SCHEMBL31209584 | 0.82 | HPGD (0.43) | HPGDRECQLEPHX1MAPTALDH1A1 | |
| SCHEMBL31209762 | 0.82 | HPGD (0.43) | HPGDRECQLEPHX1MAPTALDH1A1 | |
| SCHEMBL20587386 | 0.81 | PREP (0.48) | HPGDRECQLEPHX1CHRM2CHRM1 | |
| SCHEMBL2820842 | 0.81 | HPGD (0.46) | HPGDRECQLEPHX1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049110-B1 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-1359152-B1 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LAB (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| CN-1210277-C | Heteroaryl diazabicycloalkanes, their prepn. and use | NEUROSEARCH AS (DK) | 2005-07-13 | — | — | CN | disclosed |
| EP-1177196-B1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2004-03-10 | — | — | EP | disclosed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6552012-B2 | 3-(6-Chloro-(3-pyridazinyl))-9-methyl-3,9-diazabicyclo(4.2.1)-nonane, for example; Alzheimer's disease, Parkinson's disease, memory dysfunction, smoking cessation, drug abuse, drug dependence; cholinergic ligands | NEUROSEARCH A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| CN-1349533-A | Heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2002-05-15 | — | — | CN | disclosed |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA2 | HPGD 998/4885RECQL 4094/4885EPHX1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.